INVO Bioscience, Inc. (NASDAQ:INVO) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Robert Blum – Investor Relations Steve Shum – Chief Executive Officer Mike Campbell – Chief Operating Officer and Vice President of Business Development Andrea Goren – Chief Financial Officer Conference Call Participants John Heerdink – Vista Partners LLC Curtis Thom – Paulson Operator Good day, and welcome to the INVO Bioscience's Reports Second Quarter 2022 Financial Results Call. All parti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39701 INVO Bioscience, Inc. (Exact Name of Registrant as Specified in its Charter) | Nevada | 20-4036208 ...

INVO Bioscience, Inc. (NASDAQ:INVO) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Robert Blum - Lytham Partners, LLC, IR Steven Shum - CEO Michael Campbell - COO and VP, Business Development Andrea Goren - CFO Conference Call Participants John Heerdink - Vista Partners Operator Good day, and welcome to the INVO Bioscience First Quarter 2022 Financial Results Conference Call. Today all participants will be in a listen-only mode. [Operator Instructions]. After today's presentat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INVO Bioscience, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission Nevada 001-39701 20-4036208 (I.R.S. Employer Ide ...

Call Start: 16:30 January 1, 0000 5:34 PM ET INVO Bioscience, Inc. (NASDAQ:INVO) Q4 2021 Earnings Conference Call March 31, 2022, 4:30 PM ET Company Participants Steven Shum – Chief Executive Officer Andrea Goren – Chief Financial Officer Michael Campbell – Chief Operating Officer and Vice President, Business Development Robert Blum – Lytham Partners, LLC Conference Call Participants John Heerdink – Vista Partners, LLC Lawrence Fidel – Fidelity Investments Scott Proctor – Private Investor Operator Good day, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to INVO BIOSCIENCE, INC. (Exact name of registrant as specified in Charter) Nevada 001-39701 20-4036208 (State or other jurisdiction of incorporation or organization) (Commis ...

INVO Bioscience, Inc. (NASDAQ:INVO) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Robert Blum – Lytham Partners, LLC Steve Shum – Chief Executive Officer Mike Campbell – Chief Operating Officer and Vice President-Business Development Andrea Goren – Chief Financial Officer Conference Call Participants Kyle Bauser – Colliers Securities Scott Proctor – Platinum Point Rodney Baber – Paulson Investments John Heerdink – Vista Partners, LLC Operator Good day, and welcome to the ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INVO Bioscience, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Nevada 001-39701 20-4036208 (I.R.S. Employer Identification No.) 5582 Broadcast Court Sarasota, Florida, 34240 (Address ...

INVO Bioscience, Inc. (NASDAQ:INVO) Q2 2021 Earnings Conference Call August 16, 2021 4:30 PM ET Company Participants Robert Blum - Lytham Partners Steve Shum - CEO Mike Campbell - COO & VP of Business Development Andrea Goren - CFO Conference Call Participants Scott Henry - ROTH Capital Kyle Bauser - Colliers Securities John Heerdink - Vista Partners Rodney Baber - Paulson Ben Haynor - Alliance Global Partners Operator Good afternoon and welcome to the INVO Bioscience Second Quarter Fiscal Year 2021 Financi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INVO Bioscience, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Commission File No.) Nevada 001-39701 20-4036208 (I.R.S. Emp ...